Clinical Trial Update: WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2 [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing WAveCrest with Watchman for left atrial appendage closure in AF-related stroke has been terminated, with results posted in March 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Stroke

Drugs mentioned

• WAveCrest
• Watchman

Snippet

Sponsor: Coherex Medical | Conditions: Stroke | Phase 3 | Status: TERMINATED | Results posted: 2025-03-12